Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exametazime is a small molecule chelating agent used to prepare the radiopharmaceutical technetium Tc 99m exametazime, which is employed as a diagnostic imaging agent. When combined with the radioisotope technetium-99m, it forms a lipophilic complex that can cross cell membranes and localize in tissues of interest. The primary clinical uses are for cerebral perfusion scintigraphy to detect altered regional cerebral blood flow (such as in stroke) and for leukocyte-labeled scintigraphy to help localize intra-abdominal infections and inflammatory bowel disease. The mechanism of action involves chelation of technetium Tc 99m by exametazime, allowing the resulting complex to be taken up by target tissues or cells (notably leukocytes), enabling their visualization via nuclear medicine imaging techniques[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on exametazime.